You are here

Fosfomycin Demonstrates In Vitro Activity Against Bacteria Resistant to Last-Resort Antibiotic

First-in-class injectable antibiotic wins fast track designation

A newly emerging bacterial pathogen resistant in vitro to the “last defense” antibiotic colistin has retained susceptibility to ZTI-01 (fosfomycin for injection, Zavante Therapeutics) as well as to certain other antibiotics, according to JMI Laboratories’ SENTRY surveillance report, published in Antimicrobial Agents and Chemotherapy.

ZTI-01 is a first-in-class injectable antibiotic that has demonstrated a broad spectrum of bactericidal gram-negative and gram-positive activity in vitro, including activity against most contemporary multidrug-resistant strains.

Confirmation of the presence in the United States of a multidrug-resistant pathogen with a resistance gene (mcr-1) represents a challenge for hospital-based physicians because of the limited therapeutic options that are currently available. 

The FDA has granted a fast track designation for the investigation of ZTI-01 for the following indications:

  • Complicated urinary tract infections (cUTIs)
  • Hospital-acquired bacterial pneumonia
  • Ventilator-associated bacterial pneumonia
  • Acute bacterial skin and skin-structure infections
  • Complicated intra-abdominal infections

An epoxide intravenous antibiotic, ZTI-01 is under development for the treatment of cUTIs, including those caused by multidrug-resistant pathogens. In April 2016, Zavante initiated the ZEUS study of ZTI-01 for the treatment of cUTIs in hospitalized patients.

ZEUS is a multinational, randomized, active-controlled, double-blind trial designed to provide data to support the use of ZTI-01 for the treatment of patients with cUTIs, including those with multidrug-resistant infections. It is anticipated that the study will enroll 460 hospitalized patients. ZEUS is the single pivotal study intended to support a new drug application for ZTI-01 in the U.S. The study is expected to be completed in the second half of 2017.

Sources: Zavante Therapeutics; July 12, 2016; and Zavante Therapeutics; April 14, 2016.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time